Marken, a global clinical supply chain solutions provider, has completed the first phase of its plan to create a global pharmaceutical depot network that will allow it to satisfy its client's needs for global distribution. Two new depots have been completed: one in Frankfurt, Germany, and one in Farmingdale, New York.

The launch of these two central depots, when added to the existing operational depots in Singapore, Mexico and Argentina and further supplemented by its own third party depot network, now completes phase one of the global Marken depot network plan. This network has been built based on an extensive analysis of client needs as well as geographical needs, allowing large phase III clinical trials to be conducted in a cost efficient and optimized manner.

"Today marks an important milestone for Marken. Having these two new central depots allows us to serve our clients with global distribution services and, more importantly, to serve our clients who seek comprehensive and efficient global distribution. Phase one is complete. We are now pushing forward with phase two, which will include more depots in key countries around the world such as China, Brazil and Russia," said Gerit Offenhauser, senior vice president of clinical trials distribution, Marken.

Marken's depots provide secure temperature controlled storage and distribution for drugs, medical devices and diagnostic equipment. They are located near existing branch operations in order to take advantage of well established customer service, operations import /export and administrative support. Each of Marken's depots are connected through the Solo platform, a state-of-the-art, 21 CFR part 11 validated, cloud-based inventory management system which can interface with IRT for improved inventory reconciliation. This interface allows our client to track dosages at the patient level.

"We are proud to expand our pharmaceutical service depot network to Frankfurt and New York. Having a presence in these cities ensures that Marken continues to serve our clients with full service, global clinical supply chain solutions,” said Wes Wheeler, CEO of Marken. “Marken will continue to invest in facilities and technologies which will provide the highest quality courier and logistics services."